Tumor Growth: Doubling time 6.9 days, detectable at ~69 days, treatment at day 50 slows progression
With a growth rate of 0.1/day, the tumor doubles every 6.9 days and reaches clinical detection (1 billion cells, ~1cm) at approximately day 69. Treatment starting at day 50 combined with immune kill rate of 0.02 shifts the tumor from exponential growth to Gompertzian deceleration, potentially stabilizing it below the carrying capacity.
The Mathematics of Cancer
Cancer is fundamentally a disease of uncontrolled growth. A single cell acquires mutations that disable growth controls, and its descendants multiply relentlessly. But tumor growth is not simply exponential — it follows a Gompertzian curve, starting fast and gradually decelerating as the tumor faces physical constraints. Understanding this growth pattern is essential for treatment planning, early detection strategies, and predicting patient outcomes.
Gompertzian Growth
The Gompertz model captures a key observation: small tumors grow much faster than large ones. A 1mm tumor may double in weeks, while a 5cm tumor may take months. This deceleration occurs because large tumors outgrow their blood supply (causing central necrosis), face nutrient and oxygen limitations, and encounter increasing mechanical pressure from surrounding tissues. The model's carrying capacity K represents the maximum tumor size sustainable in a given tissue environment.
Immune Surveillance and Evasion
The immune system is not a passive bystander during tumor growth. Natural killer cells and cytotoxic T lymphocytes constantly patrol for abnormal cells, killing many nascent tumors before they ever become clinically relevant. The simulation includes this immune kill rate as a parameter. When immune killing exceeds growth, the tumor shrinks. When it falls behind, cancer progresses. Modern immunotherapy drugs (checkpoint inhibitors) work by boosting this immune kill rate — turning the balance back in the body's favor.
Treatment Timing: The Earlier, The Better
This simulation powerfully demonstrates why early detection saves lives. Drag the treatment start day earlier and watch the outcome change from uncontrolled growth to tumor regression. Smaller tumors have fewer resistant clones, better drug delivery, and a more favorable immune environment. The mathematical reality is stark: treating a tumor at 10⁸ cells is fundamentally different from treating one at 10¹¹ cells, even though the patient may feel no symptoms at either stage.
FAQ
What is Gompertzian growth?
Gompertzian growth describes how tumors grow rapidly when small but decelerate as they enlarge. Unlike simple exponential growth, the Gompertz model includes a carrying capacity — the growth rate decreases logarithmically as the tumor approaches its maximum size. This deceleration occurs because large tumors outgrow their blood supply, face nutrient limitations, and encounter increasing immune pressure.
How long does it take to detect a tumor?
A tumor typically becomes clinically detectable (by imaging or palpation) when it reaches about 1cm in diameter, corresponding to roughly 10⁹ (one billion) cells. Starting from a single mutated cell, this requires about 30 doublings. With a typical doubling time of 1-6 months, this means tumors may grow silently for years to decades before detection.
What is immune surveillance of tumors?
The immune system constantly monitors for and destroys abnormal cells — a process called immune surveillance. Cytotoxic T cells and NK cells can recognize and kill cancer cells. However, tumors evolve immune evasion mechanisms: downregulating surface markers, secreting immunosuppressive factors, and recruiting regulatory T cells. The balance between immune killing and tumor evasion determines whether a cancer grows or is eliminated.
Why does treatment timing matter?
Smaller tumors respond better to treatment for several reasons: fewer cells to kill, better blood supply delivering drugs, less genetic heterogeneity (fewer resistant clones), and stronger immune co-operation. The simulation demonstrates that treatment at 10⁸ cells is far more effective than at 10¹⁰ cells, even with identical therapy — supporting the clinical importance of early detection.